secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001683168-23-005641
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharma Q2 net loss $4.0M; Berubicin GBM trial enrollment at 180; topline data expected Q4 2023
--------------------------------------------------------------------------------

- Net loss $4.0M for Q2 2023 vs $3.6M in Q2 2022; R&D expense $2.8M (up from $2.2M).
- Cash $4.3M as of June 30, sufficient into Q4 2023 through interim data readout.
- Berubicin GBM trial enrollment ~75% (180 of 240 patients); topline interim results expected Q4 2023.
- Company reiterated upcoming milestones: enroll 200th patient in Q3, complete enrollment in Q4.
- Investigation into naked short selling; believes majority of activity identified and eliminated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823005641/0001683168-23-005641-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823005641/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-005641

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer